Achieve Life Sciences, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Achieve Life Sciences, Inc. (ACHV) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $0 for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2018-05-09
- Achieve Life Sciences, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- Achieve Life Sciences, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-12-31 was $39.00K, a 66.95% decline year-over-year.
- Achieve Life Sciences, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-09-30 was -$7.00K, a 101.13% decline year-over-year.
- Achieve Life Sciences, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-06-30 was $66.00K.
- Achieve Life Sciences, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2017 was $150.00K, a 82.82% decline from fiscal 2016.
- Achieve Life Sciences, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2016 was $873.00K, a 53.98% decline from fiscal 2015.
- Achieve Life Sciences, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2015 was $1.90M.
- Achieve Life Sciences, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2014 was -$3.74M, a 216.61% decline from fiscal 2013.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 | $39.00K derived: sum of 2 quarters · filed 2018-05-09 | $32.00K derived: sum of 3 quarters · filed 2018-05-09 | $98.00K derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $32.00K derived: sum of 2 quarters · filed 2018-03-01 | $98.00K derived: sum of 3 quarters · filed 2018-03-01 | $150.00K 10-K · filed 2018-03-01 |
| 2017-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $59.00K derived: sum of 2 quarters · filed 2017-11-09 | $111.00K 10-Q · filed 2017-11-09 | $229.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-31 | $118.00K 10-Q · filed 2017-07-31 | $236.00K derived: sum of 3 quarters · filed 2017-07-31 | $857.00K derived: sum of 4 quarters · filed 2017-07-31 |
| 2017-03-31 | $52.00K 10-Q · filed 2017-05-15 | $170.00K derived: sum of 2 quarters · filed 2017-05-15 | $791.00K derived: sum of 3 quarters · filed 2017-05-15 | $258.00K derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $739.00K derived: sum of 2 quarters · filed 2017-02-23 | $206.00K derived: sum of 3 quarters · filed 2017-02-23 | $873.00K 10-K · filed 2017-02-23 |
| 2016-09-30 | $621.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $88.00K derived: sum of 2 quarters · filed 2016-11-10 | $755.00K 10-Q · filed 2016-11-10 | $2.49M derived: sum of 4 quarters · filed 2016-11-10 |
| 2016-06-30 | -$533.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $134.00K 10-Q · filed 2016-08-04 | $1.86M derived: sum of 3 quarters · filed 2016-08-04 | $2.00M derived: sum of 4 quarters · filed 2016-08-04 |
| 2016-03-31 | $667.00K 10-Q · filed 2016-05-12 | $2.40M derived: sum of 2 quarters · filed 2016-05-12 | $2.53M derived: sum of 3 quarters · filed 2016-05-12 | $2.10M derived: sum of 4 quarters · filed 2016-05-12 |
| 2015-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $1.86M derived: sum of 2 quarters · filed 2016-03-09 | $1.43M derived: sum of 3 quarters · filed 2016-03-09 | $1.90M 10-K · filed 2016-03-09 |
| 2015-09-30 | $131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$299.00K derived: sum of 2 quarters · filed 2015-11-12 | $166.00K 10-Q · filed 2015-11-12 | -$807.00K derived: sum of 4 quarters · filed 2015-11-12 |
| 2015-06-30 | -$430.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $35.00K 10-Q · filed 2015-08-13 | -$938.00K derived: sum of 3 quarters · filed 2015-08-13 | -$3.81M derived: sum of 4 quarters · filed 2015-08-13 |
| 2015-03-31 | $465.00K 10-Q · filed 2015-05-14 | -$508.00K derived: sum of 2 quarters · filed 2015-05-14 | -$3.38M derived: sum of 3 quarters · filed 2015-05-14 | -$4.00M derived: sum of 4 quarters · filed 2015-05-14 |
| 2014-12-31 | -$973.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-26 | -$3.85M derived: sum of 2 quarters · filed 2015-03-26 | -$4.46M derived: sum of 3 quarters · filed 2015-03-26 | -$3.74M 10-K · filed 2015-03-26 |
| 2014-09-30 | -$2.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | -$3.49M derived: sum of 2 quarters · filed 2014-10-30 | -$2.77M 10-Q · filed 2014-10-30 | -$2.43M derived: sum of 4 quarters · filed 2014-10-30 |
| 2014-06-30 | -$615.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $106.00K 10-Q · filed 2014-08-07 | $440.00K derived: sum of 3 quarters · filed 2014-08-07 | $979.00K derived: sum of 4 quarters · filed 2014-08-07 |
| 2014-03-31 | $721.00K 10-Q · filed 2014-04-30 | $1.05M derived: sum of 2 quarters · filed 2014-04-30 | $1.59M derived: sum of 3 quarters · filed 2014-04-30 | $2.50M derived: sum of 4 quarters · filed 2014-04-30 |
| 2013-12-31 | $334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | $873.00K derived: sum of 2 quarters · filed 2014-03-11 | $1.77M derived: sum of 3 quarters · filed 2014-03-11 | $3.21M 10-K · filed 2014-03-11 |
| 2013-09-30 | $539.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $1.44M derived: sum of 2 quarters · filed 2013-11-07 | $2.87M 10-Q · filed 2013-11-07 | $4.81M derived: sum of 4 quarters · filed 2013-11-07 |
| 2013-06-30 | $901.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $2.33M 10-Q · filed 2013-08-08 | $4.27M derived: sum of 3 quarters · filed 2013-08-08 | $6.58M derived: sum of 4 quarters · filed 2013-08-08 |
| 2013-03-31 | $1.43M 10-Q · filed 2013-05-02 | $3.37M derived: sum of 2 quarters · filed 2013-05-02 | $5.68M derived: sum of 3 quarters · filed 2013-05-02 | |
| 2012-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-07 | $4.25M derived: sum of 2 quarters · filed 2013-03-07 | $4.46M 10-K · filed 2013-03-07 | |
| 2012-09-30 | $2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $2.52M 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | $214.00K 10-Q · filed 2012-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |